Association of antiretroviral therapy adherence and health care costs

Annals of Internal Medicine

Volumn 152, Issue 1, 2010, Pages 18-25

  Nachega, Jean B ^a   Leisegang, Rory ^b   Bishai, David ^c   Nguyen, Hoang ^d   Hislop, Michael ^e   Cleary, Susan ^f   Regensberg, Leon ^e   Maartens, Gary ^b  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Tay Ho Clinics   (Viet Nam)

^e The Boulevard   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG COST; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SOUTH AFRICA;

EID: 74849120025     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-152-1-201001050-00006     Document Type: Article

References (49)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60. [PMID: 9516219]
2. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11-9. [PMID: 16741877]
3. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-31. [PMID: 11248160]
4. Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS. 2007;21:1333-40. [PMID: 17545710]
5. Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther. 2006;11:63-72. [PMID: 16518961]
6. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Eff Resour Alloc. 2006;4:20. [PMID: 17147833]
7. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. [PMID: 10877736]
8. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-73. [PMID: 17438315]
9. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-47. [PMID: 15633092]
10. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21:965-71. [PMID: 17457090]
11. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-3. [PMID: 11416722]
12. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051-8. [PMID: 11953472]
13. Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S113-8. [PMID: 17133193]
14. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S149-55. [PMID: 17133199]
15. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999; 37:846-57. [PMID: 10493464]
16. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26:814-23. [PMID: 3398608]
17. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50: 105-16. [PMID: 9048695]
18. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response [Letter]. J Acquir Immune Defic Syndr. 2000;23:360-1. [PMID: 10836763]
19. Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander CS, Harrigan PR, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108-14. [PMID: 16991085]
20. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107-10. [PMID: 15528063]
21. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-47. [PMID: 15633092]
22. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥200 cells/μL. AIDS. 2006;20:1117-23. [PMID: 16691062]
23. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43:78-84. [PMID: 16878045]
24. Regensberg L, Makiwane M, eds. AfA Clinical Guidelines. 7th ed. Cape Town, South Africa: Aid for AIDS; 2009. Accessed at www.aidforaids.co.za /EX-Medscheme-VS07/Documents/AFA/Guidelines-book-Final.pdf on 4 November 2009.
25. Statistics South Africa. Consumer price index indices. Gauteng, Pretoria, South Africa: Statistics South Africa; 2009. Accessed at www.statssa.gov.za /keyindicators/keyindicators.asp on 4 November 2009.
26. Oanda Corporation. FXConverter-Currency Converter for 164 Currencies [Currency tool]. New York: Oanda Corporation; 2009. Accessed at www.oanda .com/convert/classic on 4 November 2009.
27. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320:1197-200. [PMID: 10784550]
28. Kilian R, Matschinger H, Löeffler W, Roick C, Angermeyer MC. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment. J Ment Health Policy Econ. 2002;5:21-31. [PMID: 12529567]
29. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24:465-88. [PMID: 15811539]
30. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998;17:283-95. [PMID: 10180919]
31. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18:153-71. [PMID: 10346351]
32. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247-81. [PMID: 10180918]
33. Jones A. Health econometrics. In: Culyer A, Newhouse J, eds. Handbook of Health Economics. Amsterdam: Elsevier; 2000:265-344.
34. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. 1967;1:221-33.
35. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48:817-30.
36. Fewell Z, Hernán MA, Wolfe F, Tilling K, Choi H, Sterne JA. Controlling for time-dependent confounding using marginal structural models. Stata Journal. 2004; 4:402-20. Accessed at www.statajournal.com/article.html? article=st0075 on 4 November 2009.
37. Gardner EM, Maravi ME, Rietmeijer C, Davidson AJ, Burman WJ. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy. 2008;6:145-55. [PMID: 19231907]
38. Purdum AG, Johnson KA, Globe DR. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting. AIDS Care. 2004; 16:767-80. [PMID: 15370064]
39. Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries. J Manag Care Pharm. 2009;15: 32-41. [PMID: 19125548]
40. de Asisi Acurcio F, Puig-Junoy J, de Fátima Bonolo P, Braga Ceccato MG, Guimarães MD. [Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil]. Rev Esp Salud Publica. 2006;80:41-54. [PMID: 16553259]
41. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197 Suppl 3:S272-8. [PMID: 18447613]
42. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5:e109. [PMID: 18494555]
43. Gross R, Bilker WB, Wang H, Chapman J. How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART? HIV Clin Trials. 2008;9:202-6. [PMID: 18547907]
44. Mills EJ, Nachega JB. A wake-up call for global access to salvage HIV drug regimens. Lancet. 2007;370:1885-7. [PMID: 18068497]
45. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34:281-8. [PMID: 14600572]
46. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16:38-41. [PMID: 15705271]
47. Walensky RP, Lindsey L, Wolfe FB, Wood R, Fofana MO, Freedberg KA, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med. 2009;151:157-66. [PMID: 19620143]
48. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-24. [PMID: 16530575]
49. Egger M. Outcomes of ART in resource-limited and industrialized countries. Abstract 62. Presented at 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles, California. Accessed at www.retroconference.org/2007/Abstracts/30600.htm on 4 November 2009.